Bone cancer

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This study tests whether adding a targeted drug called ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. The trial includes 312 participants and aims to see if the combination improves survival without the cancer growing back. The…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This early-stage trial is testing a new drug called JS207 in about 98 people with advanced cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also loo…

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…

This phase 2 study tests the drug selinexor against standard treatments in 112 people with myelofibrosis who have already tried JAK inhibitors. The main goal is to see if selinexor can shrink the spleen and improve symptoms. Participants are randomly assigned to receive either se…

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This Phase 3 trial is testing whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that lacks a specific genetic mutation (FLT3-ITD). About 700 participants will receive either quizartinib or a placebo alongsi…

This phase 2 trial compares two standard CML drugs—imatinib (Gleevec) at two different doses and dasatinib (Sprycel)—in 406 newly diagnosed patients with chronic phase CML. The main goal is to see which treatment leads to the best molecular response after 12 months, meaning a ver…

This study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…

This study tests an experimental oral drug called LY3410738 in people with advanced blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that have specific IDH1 or IDH2 gene mutations. The drug is designed to block the mutated IDH proteins that he…

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…

This study tests the drug ruxolitinib (Jakafi) in 29 people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if the drug can improve blood counts, shrink the cancer, or delay its turning into a more aggressive leukemia. Researchers are also che…

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…

This early-stage trial is testing a new drug called AOH1996 in 12 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The drug works by blocking a protein that helps cancer cells grow and repair themselves. The main goals are to fi…

This phase 1 trial is testing a combination of total marrow and lymphoid irradiation (TMLI) plus two chemotherapy drugs, fludarabine and melphalan, given before a donor stem cell transplant. The goal is to find the safest dose of radiation that can kill cancer cells while prepari…

This study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…

This early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…

This phase 3 trial compares two types of stem cell transplants for children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). One uses a half-matched family donor (haploidentical), the other a fully matched unrelated donor. The goal is to see w…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approa…

This Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …

This phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …

This phase 2 trial tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) a special type of immune cell—called a cytokine-induced memory-like natural killer (NK) cell—after a stem cell transplant can improve their chances of staying cancer-free. About 60 ad…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia (AML). About 50 participants will receive the combination to find the best dose and see how many achieve remi…

This study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …

This study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or hav…

This study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This study tests a chemotherapy drug called CPX-351 (Vyxeos) in 25 patients under 22 years old who have secondary myeloid neoplasms, a type of blood cancer that develops after previous cancer treatment. Participants receive one or two rounds of CPX-351, followed by a stem cell tr…

This phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This phase 3 trial is testing whether adding radiation therapy to standard care can prevent bone complications like fractures or spinal cord compression in cancer patients with high-risk bone metastases that aren't causing symptoms yet. About 280 patients with multiple metastatic…

This study tests whether adding two adult cancer drugs, bortezomib and vorinostat, to standard chemotherapy is safe and effective for infants with acute lymphoblastic leukemia (ALL). About 50 newly diagnosed infants will receive the combination. The goal is to see if it reduces l…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This phase II trial tests two immunotherapy drugs, oleclumab and durvalumab, in 75 people with advanced sarcoma (angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma) that has returned, spread, or stopped responding to treatment. The goal is to see if the combination can s…

This study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia (a blood disorder causing too many platelets) who did not respond well to or couldn't tolerate the standard drug hydroxyurea. About 340 adults will be ra…

This phase 2 trial tests the drug atezolizumab in 27 people with chondrosarcoma or clear cell sarcoma that cannot be removed by surgery or has spread. Atezolizumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal is to see if the drug can…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This phase II trial tests a drug called telaglenastat (CB-839) in people with advanced solid tumors that have specific genetic changes, including NF1 mutations and malignant peripheral nerve sheath tumors. The drug works by blocking an enzyme that cancer cells need to grow. Resea…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …

This early-phase trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific DNA repair mutations. The goal was to find the best dose and see if this sequence causes fewer side effects than taking both drug…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This early-phase trial tests a reduced-intensity stem cell transplant using a half-matched donor and a drug called cyclophosphamide after the transplant to prevent rejection. The goal is to see if this approach is safe enough for patients with advanced myelofibrosis, a serious bo…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This study provides extended access to the drug momelotinib for 237 people with a type of bone marrow cancer called myelofibrosis. Participants had already been taking momelotinib in earlier studies and had not seen their disease get worse. The goal is to see how safe the drug is…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…

This study tests a precise type of proton radiation (IMPT) for people with chordoma or chondrosarcoma in the spine, sacrum, or skull base. The goal is to control the tumor while reducing damage to healthy tissue. Some participants may also have surgery. The study includes 64 adul…

This phase 3 trial tests a drug called imetelstat against the best available treatments for people with advanced myelofibrosis whose disease has stopped responding to JAK inhibitors. The study includes 327 participants and aims to see if imetelstat can help them live longer and f…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase II trial is testing whether combining two targeted drugs, palbociclib and binimetinib, can help people with cancers that have RAS mutations. The study includes patients with pancreatic cancer, ovarian cancer, and other solid tumors. Researchers want to see if the drug …

This study tests whether adding the drug selinexor to standard chemotherapy can help older adults with untreated acute myeloid leukemia (AML) live longer and achieve remission. About 57 participants will receive either standard chemo alone or chemo plus selinexor, followed by mai…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…

This study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination lea…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study was designed to test whether adding olutasidenib to standard chemotherapy drugs could help control certain blood cancers in people with an IDH1 gene mutation. The trial was withdrawn before enrolling any participants, so no results are available.

This phase 2 trial tests a combination of six drugs, called the Beach regimen, in 32 adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see if this mix can bring about remission and improve survival. Participants receive the drugs in a specific schedu…

This study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…

This study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This Phase II trial is studying whether proton beam therapy, with or without standard photon radiation, can effectively treat skull base chordoma, a rare tumor at the base of the skull. Nineteen participants who had surgery to remove as much tumor as possible are receiving daily …

This study looks at whether lower doses of the chemotherapy drug CPX-351 can help older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to other treatments. The goal is to control the disease while being gentler o…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …

This phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitid…

This early study tests whether elotuzumab can help people with a specific type of myelofibrosis, a serious bone marrow disorder. The drug targets a protein on cancer cells to try to improve blood counts, shrink an enlarged spleen, and ease symptoms. The trial includes 15 adults w…

This study tests a combination of two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who haven't had treatment before. The goal is to find the safest dose and see if the combo can shrink or control …

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This early-phase trial tests a new drug called M3814 alongside three chemotherapy drugs (mitoxantrone, etoposide, and cytarabine) in 48 adults with acute myeloid leukemia that has returned or not responded to treatment. The main goal is to find the safest dose and understand side…

This early-stage trial tests a combination of two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose of momelotinib when given with gilteritini…

This study tests two drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific genetic change called a BRAF V600 mutation. The goal is to see if these drugs can shrink tumors or stop them from growing. The trial includes 44 participants with various c…

This phase 2 trial tests the drug talazoparib in 150 people with advanced cancers that have not responded to standard treatments. Participants must have specific gene changes in BRCA1, BRCA2, or related DNA repair genes. The drug works by blocking an enzyme that helps cancer cell…

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 p…

This phase 2 trial tests the drug cabozantinib in 90 patients with osteosarcoma or Ewing sarcoma that has come back or spread. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. Researchers are checking whether the canc…

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work toge…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This study tests adding the targeted drug sorafenib to standard chemotherapy (busulfan and fludarabine) before a donor stem cell transplant in adults with acute myeloid leukemia that has returned or not responded to treatment. The goal is to find the safest dose of sorafenib and …

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This early-phase trial is testing a drug called flotetuzumab in children and young adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. Flotetuzumab is an immunotherapy designed to help the body's immune cells find and attack cancer c…

This phase II trial tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission after initial treatment. The study enrolls 50 adults whose AML is in first remission but who are not ready for a stem cell transplant.…

This phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…

This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will …

This study tests a new daily pill, asciminib, against several standard drugs for people newly diagnosed with a type of leukemia called CML. About 405 adults will be randomly assigned to receive either asciminib or a standard tyrosine kinase inhibitor (TKI). The main goal is to se…

This phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so n…

This early-stage trial tests a new drug called JNJ-89853413 in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, with a second part looking a…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 partici…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…

This study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check …

This study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…

This study looks at whether choosing stem cell donors based on certain genes (KIR) in addition to standard matching can reduce the chance of leukemia returning after a bone marrow transplant. About 511 people with acute myeloid leukemia (AML) are taking part. Doctors will test do…

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tests a drug called sapablursen in 50 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. Participants currently need regular blood removal (phlebotomy) to manage their condition. The goal is to see if the drug can reduce how often …

This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted drug (quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo helps control the cancer. About 52…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …

This study tested a simplified care plan for people with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to see if following easy-to-use guidelines and getting support from APL experts could lower the number of deaths soon after starting treatment. About 200…

This phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …

This early-phase trial is testing the drug selinexor (KPT-330) in 16 children and young adults with leukemia that has come back or not responded to standard treatments. The main goal is to find the safest dose and understand side effects. The drug works by blocking a protein that…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This phase 3 trial compares two treatments for people with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). One group gets lenalidomide alone, the other gets lenalidomide plus epoetin alfa, a drug that stimulates red blood …

This early-phase trial is testing whether adding an experimental drug called Q702 to two standard leukemia drugs (azacitidine and venetoclax) is safe for people with relapsed or refractory acute myeloid leukemia (AML). About 17 adults whose leukemia has not responded to or has re…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This study tests a drug called copanlisib in 22 adults with various cancers that have lost a protein called PTEN. The drug works by blocking enzymes that help cancer cells grow and survive. The main goal is to see if the drug can shrink tumors or stop them from growing for at lea…

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that make cancer cells grow. The trial includes about 10 adults with lymphoma, solid tumors, or multiple myeloma that have not res…

This phase II trial tests the drug palbociclib in 43 patients with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to multiply. Researchers will measure how many patients' tumors shrink or stop growing f…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This phase II trial tests the drug crizotinib in 20 adults with advanced or hard-to-treat cancers that have a specific genetic change called MET exon 14 deletion. Crizotinib is a pill that blocks signals cancer cells need to grow. The study aims to see if the drug can shrink tumo…

This phase II trial is testing the drug afatinib in 19 patients with advanced solid tumors or lymphomas that have a specific EGFR mutation and have not responded to standard treatments. Afatinib works by blocking the mutated EGFR protein that helps cancer cells grow. The study ai…

This study tests whether the immunotherapy drug nivolumab can wipe out any leftover leukemia cells and prevent the cancer from returning in people with acute myeloid leukemia (AML) who are already in remission after chemotherapy. The trial enrolled 82 adults whose AML had respond…

This phase II trial tests a drug called copanlisib in 35 patients with advanced cancers that have a specific mutation in the PTEN gene. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or slow the disease. The study is small …

This study aimed to see if giving special immune cells (γδ T cells) after a stem cell transplant could help prevent leukemia from coming back in high-risk patients. It was planned for adults aged 18-65 with acute myeloid leukemia. However, the study was withdrawn before any parti…

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This phase 2 trial tests the drug vismodegib in 34 patients with advanced solid tumors, lymphoma, or multiple myeloma that have specific mutations in the SMO or PTCH1 genes. Vismodegib works by blocking a protein involved in cell growth. The main goal is to see if the drug can sh…

This study tests a pill called erdafitinib in 35 adults whose cancers have specific FGFR gene mutations or fusions. The drug blocks a faulty protein that helps cancer grow, potentially shrinking tumors or slowing the disease. It is a phase 2 trial for advanced solid tumors that h…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This phase II trial tests a drug called GSK2636771 in 24 patients whose advanced cancers have a PTEN mutation or deletion. The drug blocks a protein (PI3K-beta) that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing.

This study tests a drug called trametinib in children with a rare blood cancer (juvenile myelomonocytic leukemia) that has returned or not responded to treatment. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if it can shrink or contro…

This phase II trial tests a drug called GSK2636771 in 35 patients whose cancers have lost a protein called PTEN. The drug blocks a growth signal that these cancers may rely on. Researchers hope to see if it can shrink tumors or stop them from growing.

This early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This study tests whether asciminib is easier to tolerate than nilotinib in adults newly diagnosed with a type of leukemia called Philadelphia chromosome-positive CML. About 568 participants take either asciminib once daily or nilotinib twice daily. The main goal is to see how lon…

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This early-phase trial tests whether adding high-dose vitamin C (ascorbate) to the chemotherapy drug gemcitabine can help adults with advanced soft tissue or bone sarcoma that cannot be surgically removed or has spread. About 30 participants will receive the combination intraveno…

This early-stage trial tests two new targeted drugs (AG-120 and AG-221) given alongside standard chemotherapy for people with a specific genetic form of acute myeloid leukemia (AML). The study includes about 153 adults with newly diagnosed AML that has an IDH1 or IDH2 mutation. T…

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combo is …

This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help …

This early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy before and after a bone marrow transplant can help prevent cancer from coming back in people with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related blood…

This study looks at whether children with chronic myeloid leukemia (CML) who have very low levels of disease can stop taking their daily tyrosine kinase inhibitor (TKI) medication and still stay in remission. About 110 children will stop their TKIs and be closely monitored. If th…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This early-stage trial tests a combination of two drugs, venetoclax and azacitidine, in people with a serious type of myelodysplastic syndromes (MDS) who have not had treatment before. The goal is to find the safest dose and see how well the drugs work together to control the dis…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This study aims to find the safest and most effective initial chemotherapy for older adults (60-75) newly diagnosed with acute myeloid leukemia who can handle strong treatment. About 90 participants will be randomly assigned to one of two drug combinations or a standard treatment…

This phase II trial is testing whether combining venetoclax and azacitidine can help people with therapy-related myelodysplastic syndrome (t-MDS), a blood cancer that develops after prior cancer treatment. The study will enroll 33 adults and measure how many achieve complete remi…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests a combination of two drugs, venetoclax and decitabine, in 20 adults with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if the combination can shrink or control the cancer. Participants will take the drugs by mout…

This early-phase trial tests whether a combination of two drugs, MBG-453 and azacitidine, can eliminate leftover cancer cells in people with acute myeloid leukemia (AML). The goal is to prevent relapse by treating the disease when it is still at a very low level. Only 3 participa…

This phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regim…

This early-phase trial is testing whether adding a drug called iadademstat to the standard combination of venetoclax and azacitidine is safe and tolerable for adults with untreated acute myeloid leukemia (AML). About 45 people with intermediate- or high-risk AML will take part. T…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This trial aimed to test the drug ASTX727 (Inqovi) alone or with donor immune cells in people with blood cancers who had a stem cell transplant. The goal was to see if it could control cancer that remained or came back. However, the study was withdrawn before enrolling any patien…

This early-phase study tests a new three-drug combination for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The treatment includes a targeted radiation antibody (lintuzumab-Ac-225) plus two oral drugs (venetoclax and ASTX-727).…

This early-stage trial tests an experimental drug called INCB000928, given alone or with the standard drug ruxolitinib, for people with myelofibrosis who have severe anemia or need regular blood transfusions. The main goals are to check the drug's safety, find the right dose, and…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This study tests whether adding venetoclax to ASTX727 (a two-in-one pill) works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will be randomly assigned to one of the two trea…

This study tests a drug called ulixertinib in people with advanced cancers that have specific changes in the BRAF gene (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that ha…

This study tests a drug called MLN0128 (TAK-228) in 49 adults with advanced cancers that have TSC1 or TSC2 mutations. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if tumors shrink or stop growing, and track how long patients live or stay …

This study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…

This was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any pat…

This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This phase 2 trial tests whether adding an experimental antibody called cusatuzumab to the standard drugs venetoclax and azacitidine helps people with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 140 adults who cannot have intensive chemotherapy. P…

This early-phase study tests a stem cell transplant method for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors give specially selected immune cells (regulatory T-cells) along with regular T-cells to help the body a…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This early-phase study tests a new drug called cusatuzumab alongside usual treatments for adults with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The main goal is to check the safety and side effects of the combination. About 61 participants will receive …

This early-phase study tests a custom-made cancer vaccine (DC/AML fusion vaccine) for people with acute myeloid leukemia (AML) who have recently had a stem cell transplant. The vaccine is designed to teach the body's immune cells to recognize and attack remaining leukemia cells. …

This early-phase trial is testing a drug called AZD6738 in 52 people with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease got worse after standard therapy. The drug works by blocking a DNA repair pathway that cancer cells rely on, causing th…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This phase 2 trial tests whether a combination of two drugs, venetoclax (a pill) and azacitidine (an infusion), works better than standard intensive chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML). The study enrolls 172 fit adults and measures how long t…

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes or acute myeloid leukemia that did not improve after standard therapy. The goal is to see if the drug can improve blood cell counts and control the disease. Participants …

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors o…

This phase 2 trial tests canakinumab, an anti-inflammatory drug, in 14 to 26 people with myelofibrosis, a rare bone marrow cancer that causes scarring, enlarged spleen, and fatigue. Participants receive injections every three weeks for about six months. The study checks if the dr…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests a new drug called BMS-986158, either alone or combined with standard treatments (ruxolitinib or fedratinib), in about 216 people with high-risk myelofibrosis, a type of blood cancer. The goal is to see if the drug is safe and can shrink an enlarged spleen, a comm…

This early-phase trial tests a new targeted drug called pivekimab sunirine (PVEK) alongside a standard chemotherapy regimen (FLAG-Ida) in 30 adults with newly diagnosed, high-risk acute myeloid leukemia or related blood cancers. PVEK works like a smart bomb, attaching to a protei…

This phase 2 trial tests the drug crizotinib in patients with advanced cancers (other than lung cancer) that have a specific genetic change called ALK rearrangement. Crizotinib works by blocking the ALK protein, which may stop cancer cells from growing. The study enrolled only 5 …

This phase II trial tests the drug trametinib in 35 patients with advanced cancers that have certain BRAF mutations or fusions. The goal is to see if trametinib can shrink or stop cancer growth by blocking proteins that help cancer cells grow. The study focuses on patients whose …

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want …

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase II trial is testing the drug defactinib in 35 patients whose advanced cancers have a specific genetic change called an NF2 mutation. The drug works by blocking a protein that may help these cancer cells grow. Researchers want to see if defactinib can shrink tumors or s…

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA1 or BRCA2 gene mutation. The drug blocks a protein (WEE1) that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with various adva…

This study tests whether combining two drugs, azacitidine and quizartinib, can help people with myelodysplastic syndromes or related blood cancers that have specific genetic changes (FLT3 or CBL mutations). The trial involves 30 adults and aims to find the best dose and see how w…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, ivuxolimab, or radiation) in 173 people with advanced cancers that have not responded to standard therapies. The goal is to find tolerable doses and see i…

This study was designed to test the safety and best dose of the drug revumenib in children and young adults with certain types of leukemia (ALL, AML, or mixed phenotype) after they have received a stem cell transplant. The goal was to see if revumenib could help prevent the cance…

This phase 2 trial tests capivasertib (AZD5363) in 35 patients with advanced cancers that have an AKT mutation. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing.

This study tested a new drug called ASP2215 against standard chemotherapy in 276 adults with a specific type of acute myeloid leukemia (FLT3-mutated) that had come back or not responded to initial treatment. The goal was to see if ASP2215 helped people live longer (overall surviv…

This early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced…

This phase II trial tests the drug taselisib in 70 patients with advanced cancers (excluding breast cancer) that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if taselisib can sh…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This phase 3 trial tests imatinib, a targeted cancer drug, with two different chemotherapy backbones in children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a less intense chemo regimen works as well as the s…

This study tests a drug called luspatercept in 6 adults with lower-risk myelodysplastic syndromes (MDS) or related blood cancers who have anemia. The goal is to see if the drug can reduce or eliminate the need for regular blood transfusions. Participants receive luspatercept plus…

This clinical trial is testing different treatment strategies to improve outcomes for older adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are getting a stem cell transplant. The study compares a new pre-transplant drug (Vyxeos) with stan…

This study tests whether giving a personalized dose of a drug called r-ATG before a stem cell transplant helps the immune system recover faster and reduces serious side effects. It includes children and adults with acute leukemia or myelodysplastic syndrome (MDS) receiving a dono…

This study looks at whether people with chronic myeloid leukemia (CML) who have had a stable, deep response to treatment for at least two years can safely stop taking their daily targeted therapy (TKI). It involves 17 adults who have been on TKI for over three years. The main goa…

This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This study tests a new way of giving two drugs—venetoclax and azacitidine—to adults with acute myeloid leukemia (AML) who are not healthy enough for standard chemotherapy. Instead of the usual 7 days of azacitidine, this approach uses only 5 days per cycle to try to reduce infect…

This phase 2 trial tests a new targeted drug called sonrotoclax (taken as a pill) combined with standard chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The treatment plan is adjusted based on each patient's genetic risk and response. The goal is to s…

This phase 3 study tests a drug called pacritinib against standard treatments chosen by the doctor in people with myelofibrosis who have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and reduce symptoms like tiredness, pain, and i…

This study looks at whether people with chronic myeloid leukemia (CML) can stop taking their daily targeted therapy (TKI) without the cancer coming back. It compares two approaches: stopping the drug suddenly after a year of normal dosing, versus slowly reducing the dose over a y…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…

This study tests two drugs, selinexor and venetoclax, given together with standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find the safest dose and see how well the combination w…

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…

This study tests whether adding the drug midostaurin to standard chemotherapy helps children with a certain genetic type of acute myeloid leukemia (FLT3-mutated AML). About 22 children will receive the drug twice daily alongside chemo, then continue midostaurin alone for 12 more …

This phase II trial tests the drug decitabine in 21 patients with advanced myelofibrosis, a bone marrow cancer that causes scarring and anemia. The goal is to see if decitabine can improve blood counts and reduce the need for transfusions. Researchers are also monitoring side eff…

This phase 2 trial is testing whether an oral chemotherapy drug called azacitidine (CC-486) can help prevent acute myeloid leukemia from coming back in Chinese patients who are already in complete remission after initial treatment. About 34 participants will receive either the dr…

This early-phase trial tests a combination of two drugs—entrectinib and ASTX727—in people with a specific, hard-to-treat form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study aims to find the safest dose and watch for side effects in 13 a…

This study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…

This phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…

This phase II trial tests the drug afatinib in 40 people with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer growth. The study aims to see if the …

This early-stage trial tests whether adding the immunotherapy drug ipilimumab to the chemotherapy drug decitabine is safe and tolerable for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to treatment. About 54 p…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This study tests a drug called cobimetinib in people with a rare blood cancer (CMML) that has certain gene mutations. The goal is to see if the drug can shrink or control the cancer. Fourteen adults with either new or treatment-resistant CMML will take the drug daily in 3-week-on…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This study tests whether combining two drugs, lenvatinib and pembrolizumab, can safely shrink or control advanced soft tissue sarcomas that have spread or can't be removed by surgery. About 52 adults with specific sarcoma types will receive the combination. The goal is to measure…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests an inhaled form of interleukin-2 (IL-2), a protein that boosts the immune system, in people whose cancer has spread to the lungs. The goal is to find the best dose and see if it can shrink lung tumors. About 70 adults with cancers like melanoma, sarcoma, or kidne…

This study tests whether adding the targeted drug cabozantinib to immunotherapy (ipilimumab and nivolumab) works better than immunotherapy alone for people with advanced soft tissue sarcoma that has spread. About 66 adults with specific sarcoma types will take part. The goal is t…

This study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…

This study looks at two types of hip implants used in total hip replacement for people with metastatic bone disease (cancer that has spread to the hip bone). The goal is to see if a newer implant design (dual mobility) is as good as a standard one (constrained liner) at preventin…

This study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…

This phase 2 trial tests whether adding the targeted drug venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The study aims to see if this combination can reduce the amount of c…

This phase II trial tests whether giving a short course of azacitidine or decitabine before standard chemotherapy can improve outcomes for children with newly diagnosed acute myeloid leukemia (AML). The study enrolls 206 participants and focuses on tolerability, changes in DNA me…

This Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…

This early-phase study tests a three-drug combination (navitoclax, venetoclax, and decitabine) in adults and teens with acute myeloid leukemia that returned or didn't respond to previous treatment. The goal is to find the safest dose and see if the combo can shrink or control the…

This study offers girls from birth to age 17 the chance to freeze their ovarian tissue before medical treatments that could harm their fertility, such as chemotherapy or radiation. The tissue is removed surgically and stored. Later, if they want to have children, the tissue can b…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…

This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdr…

This study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…

This study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…

This study looks at whether writing about their experiences can improve the health of Asian American breast cancer survivors. About 192 people who finished cancer treatment in the last 5 years will take part. They will write and report how they feel, and researchers will track an…

This study tests a program called ENABLE Cornerstone, where specially trained lay coaches provide support to family caregivers of people with advanced cancer. The coaches help caregivers manage stress, improve coping skills, and plan for the future through phone or in-person sess…

This study tests whether a single high dose of psilocybin (the active ingredient in magic mushrooms) combined with specialized talk therapy can help people with advanced cancer feel less anxious and more at peace. Fifteen adults with stage IV cancer will receive the treatment and…

This study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…

This study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…

This study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can reduce severe fatigue in people with advanced solid tumors that have spread or returned. About 129 participants with incurable cancers and high fatigue levels will r…

This study looks at how well two drugs, haloperidol and lorazepam, can control severe agitation and confusion (delirium) in people with advanced cancer who are in palliative care. About 110 patients will be enrolled to compare different drug approaches. The goal is to improve com…

This study looks at whether giving the painkiller hydromorphone slowly or quickly through an IV affects how well it controls cancer pain and how likely it is to be misused. About 84 hospitalized cancer patients with moderate to severe pain will receive both a slow and a fast infu…

This study tests whether a serious video game called Strong Together can help women with advanced cancer learn self-advocacy skills. Participants play through scenarios where they make decisions for characters with cancer, learning how to communicate better with doctors and manag…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …

This study tested whether the steroid dexamethasone can reduce shortness of breath (dyspnea) in people with cancer. About 135 cancer patients with moderate to severe breathing difficulty took part. Researchers measured changes in their breathlessness over one to two weeks to see …

This study looks at whether mirtazapine, a drug often used for depression, can improve appetite in people with advanced cancer who have lost weight and have little desire to eat. About 98 patients will receive either mirtazapine or a placebo for 29 days. Researchers will track ch…

This study looks at whether a writing program called Expressive Helping can improve emotional well-being for Chinese American cancer survivors. About 108 people who finished cancer treatment within the last 5 years will write about their experiences. The goal is to see if this ap…

This study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…

This phase 2 trial tests whether dexamethasone, a steroid, can help control fatigue, pain, nausea, and other symptoms in 132 adults with advanced solid tumors. Participants take the drug or a placebo by mouth twice daily for 14 days. The main goal is to see if symptoms improve, m…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests a 9-week virtual program that helps cancer survivors build social connections and reduce loneliness. Participants work one-on-one with a facilitator to create a personalized action plan. The goal is to see if this approach improves well-being and quality of life.

This study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…

This study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…

This study tests a 12-week mobile health program for 304 young adult cancer survivors (ages 18-39) who finished treatment within the last 5 years. The program combines social support and mindfulness training to encourage moderate-to-vigorous physical activity. The goal is to see …

This phase 2 trial tests whether combining cognitive behavioral therapy, a stimulant (methylphenidate), melatonin, and light therapy can improve sleep in cancer patients. About 68 patients currently on cancer treatment who have sleep problems will participate. The study measures …

This study adapts a type of counseling called Meaning-Centered Psychotherapy for Chinese immigrants with advanced cancer. The goal is to help patients maintain a sense of meaning and purpose in life despite their illness. Researchers will interview and test the adapted program wi…

This study looks at whether cognitive behavioral therapy (CBT) can help adults with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. Participants will attend up to 7 counseling sessions to learn skills to cope with fatigue, anxiety, and depre…

This study tests whether a special type of counseling called hope-focused motivational interviewing can improve hope, self-confidence, and self-compassion in cancer patients who are getting radiation therapy. About 46 adults with early-stage cancer will be randomly assigned to re…

This trial tests whether wearing a virtual reality headset during a bone marrow biopsy or lumbar puncture can reduce pain and anxiety in cancer patients. About 60 participants will use the headset while receiving standard care. The study is currently suspended, so results are pen…

This study looks at whether taking vitamin D can reduce nerve pain caused by chemotherapy in people with low vitamin D levels. About 120 cancer patients will be split into two groups: one gets vitamin D supplements, the other gets standard care. The goal is to see if vitamin D he…

This study aims to find the best way to deliver cognitive behavioral therapy for insomnia (CBT-I) to cancer survivors who have chronic sleep problems. Researchers are comparing individual vs. group sessions and whether adding booster sessions helps. The goal is to create an effec…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This study looks at whether ginseng can reduce fatigue and improve mood in people with advanced cancer. About 165 participants take either ginseng or a placebo twice daily for 4 weeks and fill out surveys about their symptoms. The goal is to see if ginseng offers real relief from…

This study looks at whether cancer patients can use a self-guided meditation program at home to reduce anxiety and depression. About 35 patients will try techniques like deep breathing or gentle movement for two weeks. The goal is to see if this simple, low-cost approach is pract…

This study looks at whether starting palliative care early can help adults with aggressive leukemias or myelodysplastic syndrome (MDS) have a better end-of-life experience. Researchers will compare where patients die (home, hospice, or hospital) and how often they need hospital c…

This study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…

This study tests an online program designed to help people with inflammatory arthritis remain employed. The program includes eLearning modules, group video sessions, and consultations with an occupational therapist and vocational counselor. About 528 participants from three Canad…

This study looks at whether personalized exercise plans delivered through a Fitbit and a smartphone app can help cancer survivors become more physically active. Researchers will track steps, weight, quality of life, and emotional well-being in 160 adult survivors who have finishe…

This study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…

This study tests whether a high-intensity parenting program can improve learning and school functioning in Latino children being treated for leukemia or lymphoma. About 214 parents and children will take part. Parents in the high-intensity group will receive extra training in ski…

This study tests whether adding a trained community health worker (CHW) to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. 160 patients will either receive standard care or standard care plus CHW support. The…

This study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…

This study looks at whether using activity trackers and a phone app can help people with cancer reach their exercise goals during treatment. Twenty-five participants will wear the trackers for three months. The goal is to see if this approach is practical and helpful for both pat…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study collects blood and urine samples from 1,000 adults receiving radiation therapy for cancer. Researchers want to learn how radiation affects gene activity in white blood cells, damages red blood cells, and changes hormone levels. No new treatment is being tested—this is …

This study tests whether a simple mathematical formula, applied to routine CT scans, can accurately predict the size of a bone defect that will be created during surgery to remove a bone tumor. Accurate prediction could help surgeons select the right-sized donor bone graft before…

This study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …

This study looks at e-cigarette use among 500 teenage and young adult cancer survivors and tests a text-message based program to help them quit. Researchers will also interview patients and healthcare providers to find the best ways to offer this support in oncology clinics. The …

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study tests a symptom questionnaire designed for teenagers with cancer. Researchers will interview 41 adolescents aged 13-17 to see if the survey accurately captures their symptoms. The goal is to improve how doctors understand and manage symptoms in young cancer patients.

This study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…

This study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed …

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This study looks at how children with cancer and their parents handle the emotional challenges of the disease. Instead of focusing only on negative effects like posttraumatic stress, researchers also explore positive changes, such as personal growth. The study compares these fami…

This was a planned French study to collect information on chronic myeloid leukemia (CML) in young adults aged 18 to 30 who were treated with tyrosine kinase inhibitors. The goal was to describe their diagnosis, treatment choices, side effects, and quality of life. However, the st…

This study looks at a program where cancer patients report their symptoms from home using a computer or phone. A navigator helps manage those symptoms. The goal is to see if this approach improves patient care and reduces emergency visits. About 3,090 adults with cancer are takin…

This observational study at Mayo Clinic looks at how immunotherapy drugs affect balance and hearing in cancer patients. Researchers will test 50 adults before and during treatment to see if their vestibular (balance) system changes over a year. The goal is to better understand si…

This study looked at whether having more frequent contact with a clinician (at least once a week) improves satisfaction for people with long-lasting musculoskeletal conditions. Participants were split into two groups: one with standard contact and one with extra check-ins via tex…

This study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…

This study watches 242 adults with high-risk polycythemia vera (a rare blood cancer that thickens the blood) who have already had a blood clot. Researchers track health data like blood pressure, weight, and lab tests to see which factors best predict future clots. The goal is to …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how radiation and chemotherapy change the bone marrow in people with acute leukemia. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more about the effects of treatment, not to…

This study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …

This study looks at whether using text messages to screen for depression is practical and well-liked by cancer survivors. About 60 adults with cancer will be asked to respond to a short depression questionnaire via text. The goal is to see if this method works better than the usu…

This study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather pra…

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study aimed to compare a virtual voice agent with a human agent for teaching cancer patients how to use remote monitoring devices at home. Patients with lung cancer would have been randomly assigned to get instructions from either the virtual agent or a human over the phone.…

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This study tests whether a special PET/CT scan using a radioactive tracer called FLT can measure how well chemotherapy is working in people with newly diagnosed acute myeloid leukemia (AML). The scan lights up fast-growing cancer cells, and researchers want to see if it can predi…

This study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study looks at how well nutritional assessments can detect malnutrition in older adults with cancer. Researchers will follow 180 patients to see if nutrition status is linked to survival at 6 months and 1 year. The goal is to find better ways to identify and address malnutri…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study looks back at medical records of 725 older adults (over 65) with acute myeloid leukemia (AML). Researchers want to see if using a special 'fitness' score to choose treatment leads to longer survival. No new treatments are given; the goal is to learn which treatment app…

This pilot study tests whether adults aged 65 and older with acute leukemia can use a digital platform to complete health questionnaires from home. Twenty participants will fill out surveys about their quality of life and symptoms on a tablet or phone, with results sent directly …

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study looks at whether cancer patients feel their doctors show more empathy during in-person visits with protective gear (PPE) or during video calls without it. About 107 adults from MD Anderson's emergency center will share their views after a conversation with their doctor…

This study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…

This study looks at how quality of life differs among older adults (60+) newly diagnosed with acute myeloid leukemia (AML) who receive either intensive or non-intensive chemotherapy. Researchers aim to build a decision-making model that helps patients and doctors choose treatment…

This study follows 549 children, teens, and young adults with cancer to see how their immune systems respond to COVID-19 vaccines. Researchers collect blood samples to measure protective antibodies. The goal is to learn how cancer and its treatment affect vaccine effectiveness, a…

This study collects medical information from patients whose cancer has spread to the bone. The goal is to learn more about how cancer affects bones and how to prevent complications like fractures and pain. No extra tests or visits are needed—just data from regular care. The study…

This study aimed to see if tracking a specific gene mutation (c-Kit) could help predict relapse in acute myeloid leukemia patients. It planned to compare this method with current monitoring techniques. However, the study was withdrawn before enrolling any participants, so no resu…

This study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study tests whether a Norwegian clinic (NSAC) helps people with common mental health issues or muscle pain return to work sooner. 2500 adults are split into three groups: one gets treatment quickly, one waits 10-14 weeks, and one gets a basic check-up. Researchers will track…

This study looks at whether it is safe to wait before giving a second round of chemotherapy to adults newly diagnosed with acute myeloid leukemia (AML), even if a mid-treatment bone marrow biopsy shows some remaining disease. About 60 participants will receive standard first chem…

This study tests a digital platform called ConnectedNest that helps cancer patients find and connect with social services like housing assistance, food aid, and financial help. About 400 adults with cancer in Minnesota will use the platform for 90 days. Researchers will measure i…

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.

This study looks at why adults with cancer may fear taking opioid pain medication after surgery. Researchers will use questionnaires to measure barriers, fears, and medication adherence in 50 patients. The goal is to learn more about these concerns to improve pain management afte…

This study follows 500 children and young adults who received gene therapy for cancer as part of earlier trials. Researchers will monitor them for up to 15 years to detect any delayed side effects. Participants have blood tests and health check-ups at regular intervals. No new tr…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study is testing whether a liquid biopsy (a blood test that detects tumor DNA) can help predict outcomes for people with Ewing sarcoma or osteosarcoma. Researchers will collect blood samples from 340 patients at diagnosis and track their health over time. The goal is to see …

This study surveys parents of children with cancer to learn about their attitudes and beliefs regarding the risks of using opioids for pain. Pain is common in pediatric cancer, and opioids are a key treatment, but parents often hesitate or underuse them. The goal is to fill a kno…

This study analyzes tumor and blood samples from 763 people with bone cancer (osteosarcoma) to understand why some tumors resist chemotherapy. Researchers will test how cancer cells respond to drugs in the lab and look for genetic clues. The goal is to learn more about treatment …

This study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI mea…

This study looks at how the COVID-19 pandemic impacted the quality of life of 274 cancer patients who also have neuropathy (nerve pain). All participants had taken part in earlier clinical trials. Researchers want to see if there are differences between those who received a brain…

This study tests whether an AI tool can accurately summarize serious illness conversations between doctors and cancer patients. Researchers will send these summaries to doctors caring for hospitalized patients with advanced cancer. The goal is to see if the summaries are accurate…

This study looks at different ways to reach out to African American patients and their doctors to see if it helps more of them join early phase cancer treatment trials. About 134 people will take part. The goal is to find better methods to make cancer research more inclusive.

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study looks at how cancer treatment changes the social lives of adolescents and young adults aged 15 to 22. Researchers will survey patients on and off therapy about their friendships, loneliness, and family relationships. The goal is to understand their social needs and gui…

This study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…

This study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…

This study looks at whether a special health assessment for older adults with cancer can help doctors predict and reduce serious side effects from chemotherapy. About 600 patients with solid tumors will be evaluated before starting treatment. The goal is to improve care and quali…